Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
11,544 total articles
Arcadia Biosciences announced its financial results for Q4 and full year 2025, reporting a 17% increase in Zola coconut water revenues and significant reductions in SG&A expenses and net cash used in operations. The company also disclosed the termination of a proposed business combination with Roosevelt Resources and the exercise of preferred inves…
SpyGlass Pharma, a late-stage biopharmaceutical company focusing on sustained drug delivery for chronic eye conditions, completed its IPO in February 2026 raising $172.5 million to fund ongoing Phase 3 clinical trials for its BIM-IOL System, intended to treat glaucoma and ocular hypertension patients undergoing cataract surgery. The company reporte…
Xanadu Quantum Technologies Limited has successfully closed its business combination with Crane Harbor Acquisition Corp., a publicly traded SPAC, along with a $275 million PIPE financing. The company will begin trading on Nasdaq and the Toronto Stock Exchange on March 27, 2026, under the ticker symbol XNDU. Xanadu positions itself as the first pure…
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application to Brazil's ANVISA for Palsonify (paltusotine), the first once-daily oral therapy approved in the US for acromegaly. The submission follows positive Phase 3 trial results demonstrating efficacy and tolerability and complements recent regulatory progress in Europe. This ma…
Zentalis Pharmaceuticals reported its full-year 2025 financial results highlighting significant milestones in the development of azenosertib, a potentially first-in-class WEE1 inhibitor targeted at Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key operational updates include completion of dose confirmation enrollment in the DENALI Pa…
Blink Charging Co. announced its 2025 fourth quarter and full year financial results, highlighting a 45% increase in service revenues, improved operational efficiency with substantial reductions in operating expenses and cash burn, and a successful $20 million equity raise. The company is focusing on expanding its owner-operated DC fast charging ne…
Kyverna Therapeutics reported significant progress in its autoimmune CAR T therapy pipeline, particularly with miv-cel (KYV-101) showing positive clinical results in stiff person syndrome (SPS), generalized myasthenia gravis (gMG), and progressive multiple sclerosis. The company plans a Biologics License Application (BLA) submission for SPS in the …
Precision Optics Corporation, a NASDAQ-listed company specializing in advanced optical instruments for healthcare and defense/aerospace industries, has announced a proposed public offering of common stock. The offering is subject to market conditions, with proceeds intended to support the company's development and manufacturing capacity in next-gen…
Zenas BioPharma has commenced underwritten public offerings of convertible senior notes due 2032 and common stock. The company plans to use net proceeds to support the U.S. commercial launch of obexelimab, advance its clinical development pipeline including Phase 3 trials of orelabrutinib, and for general corporate purposes. The offerings are subje…
Inhibikase Therapeutics announced its full-year 2025 financial results, highlighting the initiation of a global pivotal Phase 3 clinical study (IMPROVE-PAH) for its lead drug candidate IKT-001 targeting Pulmonary Arterial Hypertension (PAH). The study design features adaptive components and is underway in over 20 countries with regulatory approvals…
Apogee Therapeutics, a Nasdaq-listed clinical-stage biotech company, successfully closed its underwritten public offering, raising approximately $403 million. The offering included 5,750,000 shares sold at $70 each and full exercise of underwriters' options. Proceeds will support the company’s development of novel biologics targeting inflammatory a…
SIGA Technologies declared a special cash dividend of $0.60 per share payable on April 23, 2026. This dividend demonstrates SIGA's strong financial position and commitment to rewarding shareholders while continuing its work in biodefense, especially smallpox preparedness amid geopolitical uncertainties.
Alamos Gold Inc. has filed its annual information form and 2025 annual report including audited financial statements with both the U.S. SEC and Canadian securities authorities. These documents are accessible online and available to shareholders upon request. The company operates gold mines in Canada and Mexico and has several growth projects underw…
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is in advanced-stage evaluation to acquire a niche contract research organization (CRO) with operations in over 20 countries, poised to add $20 million+ in annual revenue and support double-digit growth. This potential acquisition aligns with Tevogen's strategy to diversify and expand its healthcare services…
XA Investments LLC has appointed Lauren Michalak as managing director and head of product development and strategy. Michalak brings two decades of experience from Nuveen, focusing on product innovation, strategic initiatives, and capital raising. She will lead product efforts for XAI's closed-end funds and consulting clients, aiming to expand the f…
XPO, Inc., a major freight transportation provider, announced that two of its leaders, Chelsey Johnston and Molly Borkgren, have been named in the 2026 Top Women to Watch in Trucking by the Women in Trucking Association, highlighting their significant contributions and leadership in the industry.
Amesite Inc. announced a Trading Partner Agreement with a leading homecare technology platform, enabling its AI-driven NurseMagic EMR to securely connect and streamline electronic visit verification (EVV) in compliance with HIPAA and CMS regulations. This integration enhances interoperability and compliance for non-acute care providers and marks a …
GlobalFoundries filed multiple lawsuits in U.S. courts against Tower Semiconductor, alleging infringement of 11 U.S. patents covering advanced semiconductor manufacturing processes. The legal actions aim to halt Tower's importation and sales of products using these patented technologies and to seek compensation for lost profits. GF emphasizes its s…
Mixed Martial Arts Group Limited (NYSE American: MMA) announced that co-founder and renowned MMA coach John Kavanagh is taking on an expanded operational role to lead initiatives converting the global fanbase of over 700 million into active participants through structured training programs. Focus areas include military, law enforcement, first respo…
eGain Corporation has appointed Steve Pappas as Head of Innovation to lead product and market expansion efforts in AI-powered knowledge management and customer experience. Pappas brings over 20 years of enterprise SaaS experience in regulated industries and a deep focus on AI and customer experience, positioning eGain to accelerate its leadership i…
At MATS 2026, DAT Freight & Analytics, a business unit of Roper Technologies (NASDAQ: ROP), unveiled new tools including the DAT One iPhone widget and DAT Outgo factoring, alongside the Convoy Platform integration, aiming to streamline freight matching, cash flow, and automation for truckers and fleets. The company also engaged with industry profes…
Visionary Holdings Inc. (NASDAQ: GV) has entered a strategic cooperation with China-based Zhejiang Chushanji Digital Technology Co., Ltd. to leverage their offline distribution network across multiple Chinese provinces for marketing and selling Visionary's V-series anti-aging products. The collaboration targets increased market penetration within m…
Can-Fite BioPharma Ltd. announced its 2025 financial results and significant clinical progress, including positive safety data in a Phase 2a pancreatic cancer trial and a remarkable 9-year cancer-free survival in a liver cancer patient treated with Namodenoson. The company is advancing Namodenoson through Phase 3 trials for hepatocellular carcinoma…
Polyrizon Ltd., a pre-clinical-stage biotech company specializing in intranasal protective hydrogels, announced key achievements in 2025 and early 2026 including progress with the FDA on clinical trial strategies, preparation of clinical trial materials, positive preclinical results, and expansion into potential new revenue streams such as private …
Edesa Biotech announced progress in preparations for its Phase 2 clinical trial of EB06, an anti-CXCL10 monoclonal antibody targeting moderate-to-severe nonsegmental vitiligo. The company has selected JSS Medical Research as its clinical research organization and expects to begin patient enrollment and site activation by mid-2026, starting in Canad…
